Abbie Celniker is a Partner at Third Rock Ventures, investing at Seed, Series A, and Series B stages across Biotechnology, Biopharma, Health Care, the drug industry, Clinical Trials, Gene-editing, and cancer diagnostics. Third Rock Ventures is operating a $1.1 billion fund raised in June 2022 and invests across the United States, including the East Coast, Greater Boston Area, and San Francisco. Celniker has invested in companies like Merida Biosciences, Flare Therapeutics, Abata Therapeutics, Rheos Medicines, and Editas Medicine. Previously, she served as CEO at Eleven Biotherapeutics and at Taligen Therapeutics Inc.; SVP, Translational Medicine at Alexion Pharmaceuticals; Global Head of Biologics at Novartis; SVP, Pharmaceutical Sciences and Strategy and Operations at Millennium Pharmaceuticals, Inc.; VP, Protein Technologies at Wyeth Biotech; Director, Antibody Technologies and Bioanalytical Sciences at Genetics Institute; and Associate Director, Biological Assay Development at Genentech. She studied at the University of Arizona College of Medicine – Tucson and resides in Waban, Massachusetts, United States.
Abbie Celniker, Partner @ Third Rock. Profile with intro opportunities and ranking information.
Not Yet Mapped
We've created a profile for Abbie Celniker from Third Rock Ventures. Our ranking analysis and additional data will be available once our research is complete.
Rankings and detailed information coming soon
Network Strength
No ranking data available yet.
How to get an intro to Abbie
Map your path to Abbie instantly
Connect your network and Draftboard will automatically find and score the strongest paths to Abbie
That's it. Draftboard does the rest.
Rankings based on connection strength analysis - we ONLY show aggregate data, never specific connection data.